Top

Published in:

Open Access 09-05-2024 | Cytokines | REVIEW

Tumor Necrosis Factor and Interleukin Modulators for Pathologic Pain States: A Narrative Review

Authors: Alan D. Kaye, Dominique M. Perilloux, Alison M. Hawkins, Grace C. Wester, Amanda R. Ragaland, Sage V. Hebert, Julian Kim, Michael Heisler, Rucha A. Kelkar, Azem A. Chami, Sahar Shekoohi, Adam M. Kaye

Published in: Pain and Therapy | Issue 3/2024

Abstract

Chronic pain, a complex and debilitating condition, involves intricate interactions between central and peripheral inflammatory processes. Cytokines, specifically tumor necrosis factor (TNF) and interleukins (IL), are key mediators in the initiation and maintenance of chronic pain states. Sensory neurons expressing receptors for cytokines like TNF, IL-1, and IL-6 are implicated in peripheral sensitization, contributing to increased signaling of painful sensations. The potential of targeting TNF and IL for therapeutic intervention in chronic pain states is the focus of this review, with preclinical and clinical evidence supporting the use of TNF and IL modulators for pain management. The physiological and pathological roles of TNF in neuropathic pain is complex. Experimental evidence highlights the effectiveness of TNF modulation in mitigating pain symptoms in animal models and displays promising outcomes of clinical trials with TNF inhibitors, such as infliximab and etanercept. ILs, a diverse group of cytokines, including IL-1, IL-6, and IL-17, are discussed for their contributions to chronic pain through inflammation and peripheral sensitization. Specific IL modulators, such as secukinumab and tocilizumab, have shown potential in managing chronic neuropathic pain, as demonstrated in various studies and clinical trials. The pharmacokinetics, safety profiles, and challenges associated with TNF and IL modulators highlight the need for cautious medication monitoring in clinical practice. Comparative evaluations have revealed distinct efficacy and safety profiles among different cytokine modulators, emphasizing the need for personalized approaches based on the specific underlying causes of pain. Further research is necessary to elucidate the intricate mechanisms by which cytokines contribute to chronic pain, as well as to understand why they may affect pain differently in various contexts. Additionally, long-term safety profiles of cytokine modulators require more thorough investigation. This continued exploration holds the promise of enhancing our comprehension of cytokine modulation in chronic pain and shaping more potent therapeutic strategies for the future.

Zhang JM, An J. Cytokines, Inflammation and Pain. Int Anesthesiol Clin. 2007;45(2):27–37. https://doi.org/10.1097/AIA.0b013e318034194e.CrossRefPubMedPubMedCentral

Pinto LG, Pinho-Ribeiro FA, Verri WA. Editorial: cytokines and pain. front Immunol Internet. 2021. https://doi.org/10.3389/fimmu.2021.788578.CrossRef

Vanderwall AG, Milligan ED. Cytokines in pain: harnessing endogenous anti-inflammatory signaling for improved pain management. Front Immunol [Internet]. 2019. https://doi.org/10.3389/fimmu.2019.03009.CrossRefPubMed

Crosson T, Roversi K, Balood M, Othman R, Ahmadi M, Wang JC, et al. Profiling of how nociceptor neurons detect danger—new and old foes. J Intern Med. 2019;286(3):268–89. https://doi.org/10.1111/joim.12957.CrossRefPubMed

Holbrook J, Lara-Reyna S, Jarosz-Griffiths H, McDermott MF. Tumour necrosis factor signalling in health and disease. F1000Research. 2019;8:F1000 Faculty Rev-111. https://doi.org/10.12688/f1000research.17023.1.CrossRefPubMedPubMedCentral

Chu WM. Tumor necrosis factor. Cancer Lett. 2013;328(2):222–5. https://doi.org/10.1016/j.canlet.2012.10.014.CrossRefPubMed

Leung L, Cahill CM. TNF-α and neuropathic pain—a review. J Neuroinflammation. 2010;16(7):27. https://doi.org/10.1186/1742-2094-7-27.CrossRef

George A, Schmidt C, Weishaupt A, Toyka KV, Sommer C. Serial determination of tumor necrosis factor-alpha content in rat sciatic nerve after chronic constriction injury. Exp Neurol. 1999;160(1):124–32. https://doi.org/10.1006/exnr.1999.7193.CrossRefPubMed

Shubayev VI, Myers RR. Upregulation and interaction of TNFα and gelatinases A and B in painful peripheral nerve injury. Brain Res. 2000;855(1):83–9. https://doi.org/10.1016/S0006-8993(99)02321-5.CrossRefPubMed

10.

George A, Buehl A, Sommer C. Tumor necrosis factor receptor 1 and 2 proteins are differentially regulated during Wallerian degeneration of mouse sciatic nerve. Exp Neurol. 2005;192(1):163–6. https://doi.org/10.1016/j.expneurol.2004.11.002.CrossRefPubMed

11.

Wagner R, Myers RR. Endoneurial injection of TNF-α produces neuropathic pain behaviors. NeuroReport. 1996;7(18):2897. https://doi.org/10.1097/00001756-199611250-00018.CrossRefPubMed

12.

Sorkin LS, Doom CM. Epineurial application of TNF elicits an acute mechanical hyperalgesia in the awake rat. J Peripher Nerv Syst JPNS. 2000;5(2):96–100. https://doi.org/10.1046/j.1529-8027.2000.00012.x.CrossRefPubMed

13.

Empl M, Renaud S, Erne B, Fuhr P, Straube A, Schaeren-Wiemers N, et al. TNF-alpha expression in painful and nonpainful neuropathies. Neurology. 2001;56(10):1371–7. https://doi.org/10.1212/wnl.56.10.1371.CrossRefPubMed

14.

Shamji MF, Jing L, Chen J, Hwang P, Ghodsizadeh O, Friedman AH, et al. Treatment of neuroinflammation by soluble tumor necrosis factor receptor Type II fused to a thermally responsive carrier. J Neurosurg Spine. 2008;9(2):221–8. https://doi.org/10.3171/SPI/2008/9/8/221.CrossRefPubMedPubMedCentral

15.

Sommer C, Lindenlaub T, Teuteberg P, Schäfers M, Hartung T, Toyka KV. Anti-TNF-neutralizing antibodies reduce pain-related behavior in two different mouse models of painful mononeuropathy. Brain Res. 2001;913(1):86–9. https://doi.org/10.1016/s0006-8993(01)02743-3.CrossRefPubMed

16.

Svensson CI, Schäfers M, Jones TL, Powell H, Sorkin LS. Spinal blockade of TNF blocks spinal nerve ligation-induced increases in spinal P-p38. Neurosci Lett. 2005;379(3):209–13. https://doi.org/10.1016/j.neulet.2004.12.064.CrossRefPubMed

17.

Korhonen T, Karppinen J, Malmivaara A, Autio R, Niinimäki J, Paimela L, et al. Efficacy of infliximab for disc herniation-induced sciatica: one-year follow-up. Spine. 2004;29(19):2115–9. https://doi.org/10.1097/01.brs.0000141179.58778.6c.CrossRefPubMed

18.

Cohen SP, Wenzell D, Hurley RW, Kurihara C, Buckenmaier CC, Griffith S, et al. A double-blind, placebo-controlled, dose-response pilot study evaluating intradiscal etanercept in patients with chronic discogenic low back pain or lumbosacral radiculopathy. Anesthesiology. 2007;107(1):99–105. https://doi.org/10.1097/01.anes.0000267518.20363.0d.CrossRefPubMed

19.

Justiz Vaillant AA, Qurie A. Interleukin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Jan 25]. http://www.ncbi.nlm.nih.gov/books/NBK499840/.

20.

Sebba A. Pain: a review of interleukin-6 and its roles in the pain of rheumatoid arthritis. Open Access Rheumatol Res Rev. 2021;5(13):31–43. https://doi.org/10.2147/OARRR.S291388.CrossRef

21.

Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281(1):8–27. https://doi.org/10.1111/imr.12621.CrossRefPubMedPubMedCentral

22.

Totsch SK, Sorge RE. Immune system involvement in specific pain conditions. Mol Pain. 2017;1(13):1744806917724559. https://doi.org/10.1177/1744806917724559.CrossRef

23.

Kim CF, Moalem-Taylor G. Interleukin-17 contributes to neuroinflammation and neuropathic pain following peripheral nerve injury in mice. J Pain. 2011;12(3):370–83. https://doi.org/10.1016/j.jpain.2010.08.003.CrossRefPubMed

24.

Jiang X, Zhou R, Zhang Y, Zhu T, Li Q, Zhang W. Interleukin-17 as a potential therapeutic target for chronic pain. Front Immunol. 2022;29(13): 999407. https://doi.org/10.3389/fimmu.2022.999407.CrossRef

25.

Richter F, Natura G, Ebbinghaus M, von Banchet GS, Hensellek S, König C, et al. Interleukin-17 sensitizes joint nociceptors to mechanical stimuli and contributes to arthritic pain through neuronal interleukin-17 receptors in rodents. Arthritis Rheum. 2012;64(12):4125–34. https://doi.org/10.1002/art.37695.CrossRefPubMed

26.

Havrdová E, Belova A, Goloborodko A, Tisserant A, Wright A, Wallstroem E, et al. Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. J Neurol. 2016;263(7):1287–95. https://doi.org/10.1007/s00415-016-8128-x.CrossRefPubMed

27.

Luo H, Liu HZ, Zhang WW, Matsuda M, Lv N, Chen G, et al. Interleukin-17 regulates neuron-glial communications, synaptic transmission, and neuropathic pain after chemotherapy. Cell Rep. 2019;29(8):2384-2397.e5. https://doi.org/10.1016/j.celrep.2019.10.085.CrossRefPubMed

28.

Akdis M, Aab A, Altunbulakli C, Azkur K, Costa RA, Crameri R, et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2016;138(4):984–1010. https://doi.org/10.1016/j.jaci.2016.06.033.CrossRefPubMed

29.

Possible role of inflammatory mediators in tactile hypersens...: PAIN [Internet]. [cited 2024 Jan 26]. Available from: https://journals.lww.com/pain/abstract/2000/12010/possible_role_of_inflammatory_mediators_in_tactile.5.aspx DOI: https://doi.org/10.1016/S0304-3959(00)00331-6

30.

Spinal interleukin‐6 is an amplifier of arthritic pain in the rat. [cited 2024 Jan 26]; Available from: https://doi.org/10.1002/art.34384

31.

Sainoh T, Orita S, Miyagi M, Sakuma Y, Yamauchi K, Suzuki M, et al. Interleukin-6 and interleukin-6 receptor expression, localization, and involvement in pain-sensing neuron activation in a mouse intervertebral disc injury model. J Orthop Res. 2015;33(10):1508–14. https://doi.org/10.1002/jor.22925.CrossRefPubMed

32.

Gerriets V, Goyal A, Khaddour K. Tumor Necrosis Factor Inhibitors. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Jan 26]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK482425/

33.

An Overview of Cytokines and Cytokine Antagonists as Therapeutic Agents - Donnelly - 2009 - Annals of the New York Academy of Sciences - Wiley Online Library [Internet]. [cited 2024 Jan 26]. Available from: https://nyaspubs.onlinelibrary.wiley.com/doi/https://doi.org/10.1111/j.1749-6632.2009.05382.x

34.

Anakinra: Drug information - UpToDate [Internet]. [cited 2024 Jan 26]. Available from: https://www.uptodate.com/contents/anakinra-drug-information?search=anakinra&source=panel_search_result&selectedTitle=1~128&usage_type=panel&kp_tab=drug_general&display_rank=1#F135437

35.

Etanercept (including biosimilars available in Canada): Drug information - UpToDate [Internet]. [cited 2024 Jan 26]. Available from: https://www.uptodate.com/contents/etanercept-including-biosimilars-available-in-canada-drug-information?search=etanercept&source=panel_search_result&selectedTitle=1~149&usage_type=panel&kp_tab=drug_general&display_rank=1#references

36.

Infliximab (including biosimilars): Drug information - UpToDate [Internet]. [cited 2024 Jan 26]. Available from: https://www.uptodate.com/contents/infliximab-including-biosimilars-drug-information?search=infliximab&source=panel_search_result&selectedTitle=1~149&usage_type=panel&kp_tab=drug_general&display_rank=1

37.

Adalimumab (including biosimilars): Drug information - UpToDate [Internet]. [cited 2024 Jan 26]. Available from: https://www.uptodate.com/contents/adalimumab-including-biosimilars-drug-information?search=adalimumab&source=panel_search_result&selectedTitle=1~149&usage_type=panel&kp_tab=drug_general&display_rank=1

38.

Certolizumab pegol: Drug information - UpToDate [Internet]. [cited 2024 Jan 26]. Available from: https://www.uptodate.com/contents/certolizumab-pegol-drug-information?search=certolizumab%20pegol&source=panel_search_result&selectedTitle=1~68&usage_type=panel&kp_tab=drug_general&display_rank=1

39.

Golimumab: Drug information - UpToDate [Internet]. [cited 2024 Jan 26]. Available from: https://www.uptodate.com/contents/golimumab-drug-information?search=golimumab&source=panel_search_result&selectedTitle=1~67&usage_type=panel&kp_tab=drug_general&display_rank=1#F7764845

40.

Sarilumab: Drug information - UpToDate [Internet]. [cited 2024 Jan 26]. Available from: https://www.uptodate.com/contents/sarilumab-drug-information?search=sarilumab&source=panel_search_result&selectedTitle=1~23&usage_type=panel&kp_tab=drug_general&display_rank=1

41.

Tocilizumab (including biosimilars): Drug information - UpToDate [Internet]. [cited 2024 Jan 26]. Available from: https://www.uptodate.com/contents/tocilizumab-including-biosimilars-drug-information?source=auto_suggest&selectedTitle=1~1---1~4---tocili&search=tocilizumab

42.

Ohtori S, Miyagi M, Eguchi Y, Inoue G, Orita S, Ochiai N, et al. Efficacy of epidural administration of anti-interleukin-6 receptor antibody onto spinal nerve for treatment of sciatica. Eur Spine J. 2012;21(10):2079–84. https://doi.org/10.1007/s00586-012-2183-5.CrossRefPubMedPubMedCentral

43.

Bessette L, Haraoui B, Chow A, Fortin I, Dixit S, Khraishi M, et al. Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational FαsT-CAN study. Ther Adv Musculoskelet Dis. 2019;5(11):1759720X19831151. https://doi.org/10.1177/1759720X19831151.CrossRef

44.

Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015;67(6):1424–37. https://doi.org/10.1002/art.39093.CrossRefPubMed

45.

Aitken D, Laslett LL, Pan F, Haugen IK, Otahal P, Bellamy N, et al. A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis—the HUMOR trial. Osteoarthritis Cartilage. 2018;26(7):880–7. https://doi.org/10.1016/j.joca.2018.02.899.CrossRefPubMed

46.

Cohen SB, Proudman S, Kivitz AJ, Burch FX, Donohue JP, Burstein D, et al. A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis Res Ther. 2011;13(4):R125. https://doi.org/10.1186/ar3430.CrossRefPubMedPubMedCentral

47.

Hung AL, Lim M, Doshi TL. Targeting cytokines for treatment of neuropathic pain. Scand J Pain. 2017;17:287–93. https://doi.org/10.1016/j.sjpain.2017.08.002.CrossRefPubMedPubMedCentral

48.

Kuffler DP. Mechanisms for Reducing Neuropathic Pain. Mol Neurobiol. 2020;57(1):67–87. https://doi.org/10.1007/s12035-019-01757-9.CrossRefPubMed

49.

Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020;16(6):335–45. https://doi.org/10.1038/s41584-020-0419-z.CrossRefPubMedPubMedCentral

50.

Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62(2):542–52. https://doi.org/10.1002/art.27221.CrossRefPubMedPubMedCentral

Title: Tumor Necrosis Factor and Interleukin Modulators for Pathologic Pain States: A Narrative Review
Authors: Alan D. Kaye
Dominique M. Perilloux
Alison M. Hawkins
Grace C. Wester
Amanda R. Ragaland
Sage V. Hebert
Julian Kim
Michael Heisler
Rucha A. Kelkar
Azem A. Chami
Sahar Shekoohi
Adam M. Kaye
Publication date: 09-05-2024
Publisher: Springer Healthcare
Keywords: Cytokines
Neuropathic Pain
TNF-Inhibitors
Tocilizumab
Sarilumab
Infliximab
Published in: Pain and Therapy / Issue 3/2024
Print ISSN: 2193-8237
Electronic ISSN: 2193-651X
DOI: https://doi.org/10.1007/s40122-024-00603-8

Effects of Different Volumes of Ropivacaine for Pericapsular Nerve Group Block on Incidence of Quadriceps Weakness and Analgesic Efficacy Following Hip Arthroplasty: A Randomized Controlled Trial

Open Access
ORIGINAL RESEARCH

Clinical Assessment of Osteoarthritis Pain: Contemporary Scenario, Challenges, and Future Perspectives

Open Access
Osteoarthrosis
REVIEW

Ganglionic Local Opioid Analgesia at the Superior Cervical Ganglion: MRI-Verified Solution Spread

Open Access
Trigeminal Neuralgia
CASE SERIES

Acute migraine: is there still a role for conventional therapy?

Open Access
Migraine
Review

Correction: Classical TAP vs. I TAP Using the Same Dose of Local Anesthetic in Elective Cesarean Section: A Randomized Controlled Trial

Open Access
Nalbuphine
Correction

Effectiveness of Vortioxetine in Patients with Major Depressive Disorder Associated with Chronic Pain: An Observational Study in a Spanish Population

Open Access
Vortioxetine
ORIGINAL RESEARCH

Keynote series | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Watch now

Keynote webinar | Spotlight on adolescent vaping

Pediatrics
On-demand webinar

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill

Dr. Debbie Robson

Benji Horwell

Developed by: Springer Medicine

Watch now

Keynote webinar | Spotlight on modern management of frailty

Frailty in Geriatric Patients
On-demand webinar

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft

Prof. Barbara C. van Munster

Prof. Mirko Petrovic

Developed by: Springer Medicine

Watch now

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on adolescent vaping

Springer Medicine

Abstract

Please log in to get access to this content